Arvinas to Participate in Upcoming Virtual Investor Conferences
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will participate in two virtual investor conferences. Dr. John Houston, President and CEO, will speak at the Guggenheim Targeted Protein Degradation Day on March 16, 2021, and at the 33rd Annual Roth Conference on March 17, 2021. Both panel discussions will be accessible via live audio webcasts on Arvinas’ website, with replays available for 30 days. Arvinas is advancing therapies using its PROTAC® platform to address life-threatening diseases, including prostate and breast cancers.
- None.
- None.
NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences. John Houston, Ph.D., President and Chief Executive Officer, will participate in panel discussions at both conferences.
- Guggenheim Targeted Protein Degradation Day panel discussion on Tuesday, March 16, 2021 at 10:30 a.m. ET
- 33rd Annual Roth Conference panel discussion on Wednesday, March 17, 2021 at 5:00 p.m. ET
A live audio webcast of each panel will be available on Arvinas’ website at www.arvinas.com. A replay of each webcast will be archived on Arvinas’ website for 30 days following the presentation.
About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Contacts for Arvinas
Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com
Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com
FAQ
What is the date and time for Arvinas' participation in the Guggenheim conference?
When will Arvinas present at the Roth Conference?
How can I watch Arvinas' conference presentations?
What are the main products being developed by Arvinas?
What technology does Arvinas use for drug development?
